Reduced recurrence of prostate cancer with novel autologous cancer vaccine (FK- PC101) post-prostatectomy: long-term results from a...

Cellipont Bioservices and CellVax Therapeutics Expand Partnership to Advance cGMP Manufacturing of Personalized Immunotherapy FK-GI101 for GI Cancers

CellVax Therapeutics Announce First Manufacturing Batch in Phase 2 Trial of FK-PC101, a Novel Personalized Cancer Immunotherapy

Fernando Kreutz, CEO of CellVax, details how the vaccine developed, already being tested in the United States, improves the treatment of...

Click on the video to watch it on YouTube. To insert English subtitles, use the player menu.

In the future, the technology could be adapted to other types of disease.

Prostate cancer vaccine developed in Brazil could revolutionize the treatment of the diseas

The therapy was tested in Brazil and is being tested in the United States. The method uses modified tumor cells to activate the patient's im

The CellVax vaccine promises individualized treatments. After 25 years of studies in Brazil, it received the green light from the FDA,...

Treatment developed by CellVax is featured in the Brazilian press and Fernando Kreutz, CEO, is interviewed by a Brazilian TV channel.

Brazilian-Developed Cancer Vaccine Enters Testing Phase in the U.S.

CellVax Therapeutics Announces FDA Clearance of IND Application for FK-PC101, a Novel Personalized Cancer Immunotherapy

CellVax Submits IND Application for Individualized Cell-based Immunotherapy FK-PC101 with Support of Theragent

Theragent to act as partner for CellVax’s Phase II cancer therapy